KU ASH 2018 Review: Current Updates in Hematologic Diseases
Avatar

ASH December 2018 - Myeloma - BCMA CAR T Therapy for Refractory Patients

By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Frederick L. Locke
By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Frederick L. Locke
0 views
March 19, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Playlist Lymphoma and Myeloma - Cellular Therapy, Efficacy and Safety from Top Trials, Axi-cel, BCMA CAR T Therapy

06:55
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Lymphoma- Historical Perspective of CAR-T Cell T…

Feat. F. Locke
24:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIE…

Feat. F. Locke
14:52
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Lymphoma - Axi-cel as Standard of Care and Relat…

Feat. F. Locke
03:50
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Myeloma - BCMA CAR T Therapy for Refractory Pati…

Feat. F. Locke
Thumbs Up
  • March 19, 2019

Recommended

AUTOPLAY
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:35
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …

Feat. H. Hashmi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
05:35
Saurabh Chhabra

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
35:37
University of Colorado Division of Hematology

2024 Updates on Multiple Myeloma Treatment

Feat. D. Sherbenou
26:46
Samer Al Hadidi

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
03:42
Moffitt Cancer Center

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Feat. D. Hansen
35:27
Dana-Farber Cancer Institute

Advances in Multiple Myeloma 2024: From Bench to Bedside

Feat. K. Anderson
17:07
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…

Feat. M. Minnema
08:30
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "DREAMM-7 Trial - BelamafVd vs. DaraVd in …

Feat. M. Mateos
27:11
MyCancerHaven

POEMS Syndrome Management

Feat. R. Vij, D. Dingli